Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial

The requested reference [87702c0c442157f91752a2d2aea18f51de4da4aa] no longer exists in our database. It has been replaced by the current reference: [9e495dab46c7013708c88b2723ea1098ed48fb74]

Authors
Category Primary study
JournalBLOOD
Year 2021
This article has no abstract
Epistemonikos ID: 29717183db620b7542f8a4ec28f869ae90a462e4
First added on: Feb 13, 2025